RCKT · Rocket Pharmaceuticals Inc
United States · RS rating 24 · As of 2026-11-03
| Price | 2.51 USD |
|---|---|
| 1-day change | +1.6% |
| RS rating (overall / 1M / 3M / 12M) | 24 / 47 / 22 / 29 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 8 / 40 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +15.6% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +52.6% |
| Market cap (USD) | $401.6M |